References
- Perez-Ruiz F, Aniel-Quiroga MA, Herrero-Beites AM, et al. Renal clearance of uric acid is linked to insulin resistance and lower excretion of sodium in gout patients. Rheumatol Int. 2015;35:1519–1524.
- Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors [ Review]. Nature Rev Rheumatol. 2015;11:649–662.
- Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64:1431–1446.
- Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016 Jul 25. pii: annrheumdis-2016-209707. [Epub ahead of print]. DOI:10.1136/annrheumdis-2016-209707
- Dalbeth N, Choi HK, Terkeltaub R. Gout: a roadmap to approaches for improving global outcomes [Review]. Arthritis Rheumatol. 2016 Jul 7. [Epub ahead of print]. DOI: 10.1002/art.39799
- Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323–345.
- Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764.
- Liu S, Perez-Ruiz F, Miner JN. Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. Joint Bone Spine. 2016 Jun 17. pii: S1297-319X(16)30071-9. [Epub ahead of print]. DOI:10.1016/j.jbspin.2016.04.007
- Köttgen A, Albrecht E, Teumer A, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45:145–154.
- Merriman TR. An update on the genetic architecture of hyperuricemia and gout [ Review]. Arthritis Res Ther. 2015 Apr 10;17:98.
- Torres RJ, de Miguel E, Bailén R, et al. Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. J Rheumatol. 2014;41:1863–1870.
- Tan PK, Ostertag TM, Miner JN. Mechanism of high affinity inhibition of the human urate transporter URAT1. Sci Rep. 2016;6:34995.
- Merriman TR, Dalbeth N, Johnson RJ. Sugar-sweetened beverages, urate, gout and genetic interaction. Pac Health Dialog. 2014;20:31–38.
- Kydd AS, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014 Nov 14;(11):CD010457.
- Perez-Ruiz F, Sundy JS, Miner JN, et al. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016;75:1074–1080.
- Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: randomized,double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (A US-based Study). Arthritis Rheumatol. 2016 Aug 26; [Epub ahead of print]. DOI:10.1002/art.39840
- Miner J, Tan PK, Hyndman D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18:214.
- Poiley J, Steinberg AS, Choi YJ, et al. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol. 2016;68:2027–2034.
- Dua P, Gurrell R, Kirby S, et al. Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649. Clin Rheumatol. 2016;35:2045–2051.
- Perez-Ruiz F, Hernandez-Baldizon S, Herrero-Beites AM, et al. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout. Arthritis Care Res (Hoboken). 2010;62(9):1299–1305.